Publications by authors named "A Arance"
Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with previous standard dosing of 200 mg or 2 mg/kg every 3 weeks, and early results of cohort B of the phase 1 KEYNOTE-555 study. Results after ≥1 year of potential follow-up for all patients in cohort B of KEYNOTE-555 are presented. Patients aged ≥18 years with previously untreated stage III/IV melanoma received pembrolizumab 400 mg every 6 weeks for ≤18 cycles.
View Article and Find Full Text PDFArticle Synopsis
- The phase III KEYNOTE-913 study focused on assessing the effectiveness and safety of pembrolizumab as a first-line treatment for advanced Merkel cell carcinoma (MCC).
- Results indicated a 49% objective response rate among the 55 patients treated, with a median duration of response of 39.8 months and median overall survival of 24.3 months.
- The treatment showed manageable side effects, with 69% of patients experiencing any grade adverse events, but only 24% facing severe issues, highlighting pembrolizumab's potential in this patient group.
Introduction: Approximately 50 % of resected stage II-IV melanoma patients develop recurrent disease by 5 years despite adjuvant anti-PD-1 therapy. Data to define best management of recurrences is lacking.
Methods: This was a multicentre, international, retrospective cohort study.